+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Pain Management Market by Drug Class, Route Of Administration, Distribution Channel, End User, Application - Global Forecast to 2030- Product Image
Cancer Pain Management Market by Drug Class, Route Of Administration, Distribution Channel, End User, Application - Global Forecast to 2030- Product Image
Sale

Cancer Pain Management Market by Drug Class, Route Of Administration, Distribution Channel, End User, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924846
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Pain Management Market grew from USD 7.86 billion in 2024 to USD 8.35 billion in 2025. It is expected to continue growing at a CAGR of 6.13%, reaching USD 11.24 billion by 2030.

Setting the Stage for Cancer Pain Management Innovations

Cancer-related pain presents a multifaceted challenge that demands an evolved approach to both clinical care and strategic planning. Patients experiencing chronic discomfort from tumors, treatment side effects, or neuropathic conditions require integrative therapies supported by robust market infrastructure. The convergence of novel analgesic compounds, advanced drug delivery technologies, and shifting reimbursement landscapes underscores the urgency for stakeholders to adopt data-driven strategies.

In this context, the executive summary offers a clear synthesis of the current state of cancer pain management, distilling complex market dynamics into actionable insights. By exploring the interplay between regulatory changes, evolving patient needs, and competitive positioning, readers will gain a holistic understanding of the forces shaping this critical therapeutic area. This introduction lays the groundwork for a deeper examination of transformative trends, tariff impacts, segmentation nuances, regional variations, and strategic imperatives.

Evolutionary Shifts Reshaping Cancer Pain Treatment

Over the past decade, the cancer pain management landscape has undergone a profound transformation driven by breakthroughs in pharmacology and drug delivery. Precision medicine initiatives have prioritized patient-centric dosing regimens, paving the way for personalized analgesic protocols. In parallel, non-invasive administration routes have gained traction as clinicians seek to minimize systemic exposure and optimize therapeutic indices.

Regulatory bodies have responded with streamlined pathways for targeted agents and combination therapies, accelerating time to market for novel candidates. As real-world evidence becomes increasingly integral to approval processes, manufacturers are investing in post-market surveillance to demonstrate long-term safety and efficacy profiles. This shift has expanded the scope of permissible indications, fostering competitive differentiation.

Ultimately, these evolutionary shifts have reconfigured stakeholder expectations and funding priorities. Investors and developers are now focusing on high-value segments that address unmet needs such as neuropathic and visceral pain. As a result, the competitive environment has intensified, compelling organizations to leverage advanced analytics and cross-functional collaboration to maintain a leadership position in this dynamic market.

Assessing the Effects of 2025 US Tariffs on Pain Management

The introduction of cumulative United States tariffs in 2025 has introduced new complexities into the cancer pain management supply chain. Increased duties on active pharmaceutical ingredients and finished formulations have elevated production costs, prompting manufacturers to reevaluate sourcing strategies. Many companies have shifted procurement to domestic suppliers or diversified their supplier base to mitigate exposure to trade fluctuations.

Price pressures have reverberated through reimbursement negotiations, with payers scrutinizing formulary placements and demanding evidence of cost-effectiveness. In response, firms have accelerated the adoption of value-based contracting models, linking reimbursement rates to patient outcomes and adherence metrics. This approach aims to preserve market access while aligning stakeholder incentives around therapeutic performance.

Despite initial disruptions, the new tariff environment has also created opportunities for innovation in local manufacturing and process optimization. Companies that have invested in advanced continuous manufacturing platforms report reductions in per-unit costs and improved supply chain visibility. As a result, the industry appears poised to adapt to these regulatory headwinds and emerge more resilient in the face of future trade policy shifts.

Unlocking Market Layers Through Detailed Segmentation

Analyzing the market through a drug class perspective reveals distinct growth trajectories for each category. Adjuvant analgesics, including anticonvulsants, antidepressants, and corticosteroids, have gained prominence for their role in modulating neuropathic pain pathways. Local anesthetics complement these treatments by providing targeted relief during acute interventions, while NSAIDs continue to serve as first-line agents for inflammatory pain. The opioid segment, further divided into natural, semi-synthetic, and synthetic compounds, remains central to moderate-to-severe pain management but faces intensified scrutiny due to safety concerns.

Evaluating the market by route of administration highlights a clear preference for oral formulations, with capsules, solutions, and tablets enabling convenient dosing regimens. Parenteral options such as intramuscular, intravenous, and subcutaneous routes deliver rapid onset in inpatient settings, and sublingual films and lozenges offer emergent relief with minimal invasiveness. Transdermal patches are gaining traction as they ensure steady-state delivery, improving patient adherence and reducing peak-trough fluctuations.

When considering distribution channels, hospital pharmacies are pivotal for administering complex therapies and managing inpatient workflows, while online pharmacies provide remote access and home delivery options. Retail pharmacies continue to serve as the primary touchpoint for outpatient prescriptions, offering patient education and adherence support. This channel mix underscores the need for integrated distribution strategies that bridge clinical and non-clinical environments.

From an end-user standpoint, cancer institutes drive protocol development and high-volume procurement of specialized analgesics, whereas hospitals balance acute care needs with broader formulary management. Home care settings are expanding rapidly, reflecting patient and caregiver preference for comfort and convenience outside institutional facilities. Finally, applications in bone metastasis pain, neuropathic pain, and visceral pain shape clinical decision-making, as each subtype demands tailored pharmacological and supportive care approaches.

Regional Dynamics Driving Cancer Pain Management Demand

The Americas region remains a dominant force, driven by advanced health infrastructure, strong reimbursement frameworks, and significant investment in research and development. North America, in particular, benefits from a robust clinical trial landscape and widespread adoption of innovative drug delivery systems. Latin America presents emerging opportunities as regulatory harmonization and increasing healthcare budgets support greater market penetration.

Europe, Middle East & Africa display heterogeneous growth patterns shaped by local regulatory regimes and varying access to specialty care. Western Europe leads adoption of cost-effective therapies, while the Middle East emphasizes centralized procurement and strategic partnerships to secure supply. Sub-Saharan Africa, despite infrastructural challenges, is witnessing gradual improvements in cancer care capabilities through global health initiatives and public-private collaborations.

Asia-Pacific is characterized by rapid expansion, fueled by rising cancer incidence, growing middle-class populations, and government-led healthcare reforms. China and India spearhead market growth through large-scale generics production and localized innovation. Southeast Asia and Oceania are also on an upward trajectory, as telemedicine and digital health solutions enhance pain management outreach in remote communities.

Strategic Moves by Leading Innovators in Pain Management

Leading pharmaceutical and biotechnology companies are prioritizing strategic alliances to bolster their oncology pain portfolios. Several major players have entered joint ventures with specialty firms to co-develop next-generation analgesics, leveraging combined expertise in formulation science and clinical development. Concurrently, licensing agreements for proprietary molecules have accelerated market entry into underserved regions, diversifying revenue streams.

Significant investments in research pipelines highlight an industry focus on non-opioid modalities and novel delivery platforms. Innovators are exploring peptide-based analgesics, targeted nanocarriers, and gene therapy approaches to achieve precise pain control with reduced systemic toxicity. Partnerships with academic institutions and contract research organizations have streamlined early-phase trials, expediting go-to-market timelines.

At the same time, established manufacturers are optimizing their branded portfolios through reformulation of existing analgesics into extended-release, transdermal, and subcutaneous systems. These initiatives aim to capture incremental value, extend patent lifecycles, and meet evolving clinical preferences. As competition intensifies, companies that align scientific innovation with real-world insights will secure sustainable advantages.

Roadmap for Leaders to Capitalize on Emerging Opportunities

Industry leaders can harness emerging opportunities by forging cross-sector partnerships that integrate digital health tools with pharmacological therapies. Incorporating remote patient monitoring and real-time data analytics into pain management protocols enhances adherence tracking, enables early intervention for adverse events, and supports value-based reimbursement negotiations.

Manufacturers should also prioritize investments in continuous manufacturing and supply chain digitization to mitigate tariff impacts and optimize cost structures. By deploying analytics-driven demand forecasting, companies can reduce inventory carrying costs and ensure consistent product availability across diverse markets.

Furthermore, tailoring market access strategies to regional payment models and clinical pathways will maximize uptake. Engaging early with health technology assessment bodies and patient advocacy groups fosters collaborative development of reimbursement dossiers that reflect both economic and humanistic outcomes.

Robust Methodology Underpinning Market Intelligence

This research synthesizes data from primary interviews with oncologists, pharmacists, payers, and patient advocacy organizations, complemented by secondary sources including regulatory filings, clinical trial registries, and peer-reviewed publications. A rigorous cross-validation process ensured data integrity, employing triangulation techniques to reconcile conflicting information and identify core market trends.

Quantitative analysis of historical sales data and patent expiration timelines was augmented by qualitative insights from key opinion leaders. The combination of top-down and bottom-up modeling approaches provided a balanced perspective on market structure, competitive intensity, and potential barriers to entry. Quality assurance protocols, including peer review and methodological audits, underpin the credibility of the findings.

Synthesis and Forward-Looking Perspectives on Cancer Pain Care

The landscape of cancer pain management is at an inflection point, shaped by technological innovation, evolving patient expectations, and dynamic policy environments. As therapies become more targeted and delivery systems more sophisticated, stakeholders must remain agile to capitalize on shifting market dynamics.

By integrating the insights presented here-ranging from tariff implications to segmentation analysis and regional trends-decision-makers can craft strategies that align scientific potential with commercial viability. The future of cancer pain care hinges on a holistic approach that balances efficacy, safety, and access to deliver meaningful improvements in patient quality of life.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Adjuvant Analgesics
      • Anticonvulsants
      • Antidepressants
      • Corticosteroids
    • Local Anesthetics
    • Nsaids
    • Opioids
      • Natural
      • Semi-Synthetic
      • Synthetic
  • Route Of Administration
    • Oral
      • Capsules
      • Solutions
      • Tablets
    • Parenteral
      • Intramuscular
      • Intravenous
      • Subcutaneous
    • Sublingual
      • Films
      • Lozenges
    • Transdermal
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Cancer Institutes
    • Home Care
    • Hospitals
  • Application
    • Bone Metastasis Pain
    • Neuropathic Pain
    • Visceral Pain
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Pfizer Inc.
  • Viatris Inc.
  • Endo International plc
  • Hikma Pharmaceuticals PLC
  • Grünenthal GmbH
  • Mallinckrodt Pharmaceuticals
  • Purdue Pharma L.P.
  • Mayne Pharma Group Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Pain Management Market, by Drug Class
8.1. Introduction
8.2. Adjuvant Analgesics
8.2.1. Anticonvulsants
8.2.2. Antidepressants
8.2.3. Corticosteroids
8.3. Local Anesthetics
8.4. Nsaids
8.5. Opioids
8.5.1. Natural
8.5.2. Semi-Synthetic
8.5.3. Synthetic
9. Cancer Pain Management Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.2.1. Capsules
9.2.2. Solutions
9.2.3. Tablets
9.3. Parenteral
9.3.1. Intramuscular
9.3.2. Intravenous
9.3.3. Subcutaneous
9.4. Sublingual
9.4.1. Films
9.4.2. Lozenges
9.5. Transdermal
10. Cancer Pain Management Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Cancer Pain Management Market, by End User
11.1. Introduction
11.2. Cancer Institutes
11.3. Home Care
11.4. Hospitals
12. Cancer Pain Management Market, by Application
12.1. Introduction
12.2. Bone Metastasis Pain
12.3. Neuropathic Pain
12.4. Visceral Pain
13. Americas Cancer Pain Management Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cancer Pain Management Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cancer Pain Management Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Teva Pharmaceutical Industries Ltd.
16.3.2. Johnson & Johnson
16.3.3. Pfizer Inc.
16.3.4. Viatris Inc.
16.3.5. Endo International plc
16.3.6. Hikma Pharmaceuticals PLC
16.3.7. Grünenthal GmbH
16.3.8. Mallinckrodt Pharmaceuticals
16.3.9. Purdue Pharma L.P.
16.3.10. Mayne Pharma Group Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CANCER PAIN MANAGEMENT MARKET MULTI-CURRENCY
FIGURE 2. CANCER PAIN MANAGEMENT MARKET MULTI-LANGUAGE
FIGURE 3. CANCER PAIN MANAGEMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CANCER PAIN MANAGEMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 69. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 71. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 72. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 74. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 75. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 76. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 84. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 132. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 135. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 136. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 137. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 142. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 145. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 146. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 162. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 163. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 165. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 166. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 167. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 172. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 175. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 176. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 177. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 212. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 215. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 216. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 217. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 232. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 233. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 235. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 236. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 237. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 242. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 245. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 246. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 247. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 272. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 275. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 276. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 277. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 282. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 285. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 286. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 287. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 300. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 301. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 302. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 303. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 305. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 306. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 307. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 310. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 311. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 312. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 313. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 315. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 316. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 317. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 330. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 335. ASIA-PACIFI

Companies Mentioned

The companies profiled in this Cancer Pain Management market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Pfizer Inc.
  • Viatris Inc.
  • Endo International plc
  • Hikma Pharmaceuticals PLC
  • Grünenthal GmbH
  • Mallinckrodt Pharmaceuticals
  • Purdue Pharma L.P.
  • Mayne Pharma Group Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.35 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.24 Billion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Pain Management Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Pain Management Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Pain Management Devices Market by Device Type, Application, Distribution Channel, End User, Mode of Purchase - Global Forecast to 2030 - Product Image

Pain Management Devices Market by Device Type, Application, Distribution Channel, End User, Mode of Purchase - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Pain Management Devices Market Size, Share & Trends Analysis Report By Application (Neuropathic, Cancer), By Product (Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion Pump), By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Pain Management Devices Market Size, Share & Trends Analysis Report By Application (Neuropathic, Cancer), By Product (Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion Pump), By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 140 Pages
  • Global
From
Post Operative Pain Management Global Market Report 2025 - Product Image

Post Operative Pain Management Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Pain Management Drugs Market Report by Drug Class, Indication, Distribution Channel, and Region 2025-2033 - Product Image

Pain Management Drugs Market Report by Drug Class, Indication, Distribution Channel, and Region 2025-2033

  • Report
  • 149 Pages
  • Global
From

About the Cancer Pain Management Market

The Cancer Pain Management market within the context of Palliative Care is focused on providing relief from the physical and psychological symptoms of cancer. This includes managing pain, fatigue, nausea, depression, anxiety, and other symptoms. Pain management strategies may include medications, physical therapy, psychological counseling, and other treatments. Palliative care also includes providing emotional and spiritual support to patients and their families. Companies in the Cancer Pain Management market include pharmaceutical companies, medical device manufacturers, and healthcare providers. Examples include Pfizer, Merck, Johnson & Johnson, Novartis, and AbbVie. Additionally, there are a number of specialized companies that focus on providing palliative care services, such as Hospice Care, Inc., and Comfort Care Hospice. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.